Tourette Syndrome and Tic Disorders.

Area of Science:

• Neurology
• Psychiatry
• Clinical Medicine

Background:

• Tourette syndrome (TS) and tic disorders present complex clinical features, etiologies, and pathophysiologies.
• Myths surrounding tic disorders often complicate patient understanding and management.
• The COVID-19 pandemic saw an increase in functional ticlike behavior, necessitating refined diagnostic criteria.

Purpose of the Study:

• To delineate clinical features, diagnostic criteria, etiology, and pathophysiology of Tourette syndrome.
• To explore various treatment modalities for tic disorders, including behavioral, pharmacologic, and neuromodulation approaches.
• To address common misconceptions about tic disorders and highlight recent advancements.

Main Methods:

• Review of clinical features and diagnostic criteria for Tourette syndrome and tic disorders.
• Discussion of current and emerging treatment strategies, including comprehensive behavioral intervention for tics (CBIT).
• Evaluation of pharmacologic trials, including vesicular monoamine transporter 2 inhibitors and ecopipam, and neuromodulation techniques like deep brain stimulation.

Main Results:

• While some pharmacologic trials for vesicular monoamine transporter 2 inhibitors did not meet primary endpoints, they may serve as add-on therapy.
• Ecopipam demonstrated efficacy and tolerability in tic reduction, representing a promising new treatment for Tourette syndrome.
• Modified CBIT approaches are being developed to enhance accessibility.
• Deep brain stimulation is a consideration for refractory cases.

Conclusions:

• Effective management of Tourette syndrome and tic disorders requires patient education on disease course and individualized treatment selection.
• Treatment choice should consider comorbidities, tic severity, and patient preferences for optimal outcomes.
• Emerging treatments offer new hope for individuals with Tourette syndrome and tic disorders.